Fischer Medical Ventures Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹82Cr
- +249.5% YoY
- −16% QoQ
- Net profit
- ₹4Cr
- −22% YoY
- Turned profitable QoQ
- Margin
- 13.73%
- −3.3 pp YoY
- +17.6 pp QoQ
Guidance rank: #10 of 13 in Healthcare Equipment & Supplies
See the sector's top 10 — free with your mobile number.
Based on Fischer Medical Ventures Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
Revenue & Sales Performance
See what Fischer Medical Ventures Ltd said on revenue & sales performance — free account, 30 seconds.
Profitability & Margins
See what Fischer Medical Ventures Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Fischer Medical Ventures Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fischer Medical Ventures Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fischer Medical Ventures Ltd said on order book & pipeline — free account, 30 seconds.
Fischer Medical Ventures Ltd — Quarterly revenue & net profit
Fischer Medical Ventures Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 |
|---|---|
| Revenue | 82 |
| Operating profit (EBITDA) | 11 |
| Operating margin | 13.7% |
| Profit before tax | 8 |
| Net profit (PAT) | 4 |
| EPS (₹) | 0.06 |
Source: Fischer Medical Ventures Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹107 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fischer Medical's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Nureca (Q1 FY27)
Revenue from Operations for Q1 FY'27: ₹40.3 Cr . Key investor presentation takeaways from Nureca's Q1 FY27 investor presentation — and how it ranks against sect
- Avience Biomedicals (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
- QMS Medical (Q1 FY27)
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Molbio DiagnostiGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fischer Medical Ventures Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What is Fischer Medical Ventures Ltd share price analysis?
Fischer Medical Ventures Ltd currently shows a neutral. The stock trades at a P/E of 94.6 with a market cap of ₹2,316 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Fischer Medical Ventures Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
